Daiichi Sankyo UK Revenue and Competitors

Gerrards Cross, UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Daiichi Sankyo UK's estimated annual revenue is currently $35.6M per year.(i)
  • Daiichi Sankyo UK's estimated revenue per employee is $201,000

Employee Data

  • Daiichi Sankyo UK has 177 Employees.(i)
  • Daiichi Sankyo UK grew their employee count by 4% last year.

Daiichi Sankyo UK's People

NameTitleEmail/Phone
1
Head Regional Access Management - NorthReveal Email/Phone
2
Head MarketingReveal Email/Phone
3
VP OncologyReveal Email/Phone
4
Marketing DirectorReveal Email/Phone
5
Medical Director UK- CardiologyReveal Email/Phone
6
HR DirectorReveal Email/Phone
7
Regional Business DirectorReveal Email/Phone
8
Senior Director, Quantitative Systems Pharmacology at Daiichi SankyoReveal Email/Phone
9
Associate Director, External Affairs and Market AccessReveal Email/Phone
10
Director Clinical Safety and PharmacovigilanceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$58.9M2936%N/AN/A
#2
$21.1M1055%N/AN/A
#3
$113.4M5641%N/AN/A
#4
$20.9M104-5%N/AN/A
#5
$37M1849%N/AN/A
#6
$45.4M226-24%N/AN/A
#7
$16.1MN/AN/AN/A
#8
$69.7M3470%N/AN/A
#9
$8M403%N/AN/A
#10
$25.5M12728%N/AN/A
Add Company

What Is Daiichi Sankyo UK?

Daiichi Sankyo UK is part of the Daiichi Sankyo group – a top 20 global pharmaceutical company with headquarters in Tokyo. We will soon be launching new products with the aim of improving patient outcomes and delivering value in partnership with the NHS. Kaizen Healthcare is our approach to identifying new and value-adding ways of partnering with the NHS to improve patient outcomes. We are committed to placing our stakeholders at the centre of everything we do. To make this a reality, we've changed our approach by enabling the entire organisation to live the principles of Key Account Management.

keywords:N/A

N/A

Total Funding

177

Number of Employees

$35.6M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Daiichi Sankyo UK News

2022-04-17 - Enhertu granted Priority Review in the US for patients with ...

AstraZeneca and Daiichi Sankyo have received notification of acceptance of the ... Based in Cambridge, UK, AstraZeneca operates in over 100...

2022-04-17 - AstraZeneca and Daiichi Sankyo Score Priority Review in ...

Lineage Cell Therapeutics also announced that Cancer Research UK had completed patient enrollment in the ongoing Phase I trial of VAC2, an...

2022-04-17 - AstraZeneca's Enhertu granted 'Priority Review'

AstraZeneca and Daiichi Sankyo announced that in the United States, Enhertu was granted Priority Review for patients with HER2-mutant metastatic...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$31.9M200-6%N/A
#2
$59.3M2637%N/A
#3
$214.6M59223%N/A